Esposito Pamela
SEC CIK 1744425 · EDGAR
BoughtSold
Most active insiders at KYMR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Booth Bruce | Dir | — | $226.03M |
| 2 | BVF PARTNERS L P/IL | Dir, See Remarks, Footnotes | — | $173.67M |
| 3 | BAKER FELIX | Dir, 10% | $172.50M | — |
| 4 | Mainolfi Nello | CEO, Dir | — | $33.41M |
| 5 | Chadwick Jeremy G | COO | — | $15.60M |
| 6 | Jacobs Bruce N. | CFO | — | $9.96M |
| 7 | Gollob Jared | Chief Medical Off | — | $9.13M |
| 8 | Esposito Pamela | Dir | — | $3.05M |
| 9 | Goodman Noah | Chief Business Off | — | $2.22M |
| 10 | Ridloff Elena | Dir | — | $1.29M |
Transactions 37
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-19 16:05 | 2026-05-19 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | M - OptEx | $31.20 | +1,000 | 1,000 | New | +$31.2K |
| DMT | 2026-03-20 | 2026-03-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $79.15 | -2,500 | 1,800 | -58% | -$197.9K |
| DT | 2026-03-20 | 2026-03-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | M - OptEx | $49.10 | +2,500 | 2,500 | New | +$122.8K |
| DT | 2026-02-20 | 2026-02-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | M - OptEx | $49.10 | +2,500 | 2,500 | New | +$122.8K |
| DMT | 2026-02-20 | 2026-02-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $87.31 | -2,500 | 0 | -100% | -$218.3K |
| DMT | 2026-01-20 | 2026-01-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $67.91 | -5,500 | 200 | -96% | -$373.5K |
| DMT | 2026-01-20 | 2026-01-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | M - OptEx | $39.34 | +5,500 | 5,500 | New | +$216.3K |
| DMT | 2025-12-17 | 2025-12-17 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | M - OptEx | $37.82 | +27.6K | 12.6K | New | +$1.04M |
| DMT | 2025-12-17 | 2025-12-17 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $82.16 | -27.6K | 13.1K | -68% | -$2.26M |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $49.04 | -5,000 | 0 | -100% | -$245.2K |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | M - OptEx | $29.55 | +5,000 | 5,000 | New | +$147.8K |
| DT | 2024-12-02 | 2024-12-02 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | M - OptEx | $29.55 | +2,500 | 2,500 | New | +$73.9K |
| DT | 2024-12-02 | 2024-12-02 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $49.00 | -2,500 | 0 | -100% | -$122.5K |
| DMT | 2024-09-17 | 2024-09-17 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | M - OptEx | $23.86 | +13.5K | 13.5K | New | +$322.1K |
| DMT | 2024-09-17 | 2024-09-17 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $48.28 | -13.5K | 0 | -100% | -$651.8K |
| DM | 2023-09-13 | 2023-09-11+ | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | M - OptEx | $3.30 | +5,658 | 263.7K | +2% | +$18.7K |
| DM | 2023-09-13 | 2023-09-11+ | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale+OE | $20.01 | -5,658 | 263.4K | -2% | -$113.2K |
| DM | 2023-08-24 | 2023-08-22 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | M - OptEx | $6.58 | +18.6K | 282.0K | +7% | +$122.4K |
| D | 2023-08-24 | 2023-08-22 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale+OE | $20.01 | -18.6K | 263.4K | -7% | -$372.2K |
| D | 2023-08-15 | 2023-08-11 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | M - OptEx | $3.30 | +1,400 | 264.8K | +0.5% | +$4,620 |
| D | 2023-08-15 | 2023-08-11 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale+OE | $20.00 | -1,400 | 263.4K | -0.5% | -$28.0K |
| DM | 2023-07-11 | 2023-07-10 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale+OE | $21.58 | -20.0K | 263.4K | -7% | -$431.5K |
| DM | 2023-07-11 | 2023-07-10 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | M - OptEx | $6.35 | +20.0K | 278.4K | +8% | +$127.0K |
| 2023-05-18 | 2023-05-16 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale | $18.05 | -5,966 | 263.4K | -2% | -$107.7K | |
| D | 2023-04-04 | 2023-04-01 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | A - Grant | $0.00 | +40.0K | 269.4K | +17% | $0 |
| D | 2022-12-13 | 2022-12-09 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | M - OptEx | $1.01 | +15.0K | 244.4K | +7% | +$15.2K |
| D | 2022-12-13 | 2022-12-09 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale+OE | $25.03 | -15.0K | 229.4K | -6% | -$375.4K |
| 2022-05-18 | 2022-05-16 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale | $14.59 | -3,507 | 229.4K | -2% | -$51.2K | |
| D | 2022-04-05 | 2022-04-01 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | A - Grant | $0.00 | +22.8K | 232.9K | +11% | $0 |
| DM | 2021-08-06 | 2021-08-04+ | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | M - OptEx | $15.50 | +30.0K | 236.0K | +15% | +$465.0K |
| DM | 2021-08-06 | 2021-08-04+ | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale+OE | $35.08 | -30.0K | 210.2K | -12% | -$1.05M |
| DM | 2021-07-22 | 2021-07-20+ | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale+OE | $33.14 | -17.4K | 210.2K | -8% | -$576.6K |
| DM | 2021-07-22 | 2021-07-20+ | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | M - OptEx | $1.01 | +17.4K | 215.0K | +9% | +$17.6K |
| DMA | 2021-07-19 | 2021-01-14+ | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale+OE | $43.99 | -55.0K | 176.0K | -24% | -$2.42M |
| DMA | 2021-07-19 | 2021-01-14+ | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | M - OptEx | $1.01 | +55.0K | 181.7K | +43% | +$55.5K |
| D | 2021-07-19 | 2021-07-15 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | M - OptEx | $1.01 | +4,600 | 214.8K | +2% | +$4,646 |
| D | 2021-07-19 | 2021-07-15 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Off | S - Sale+OE | $33.37 | -4,600 | 210.2K | -2% | -$153.5K |
Purchase Sale Sale after option exercise All abbreviations